The estimated Net Worth of Richard A Waldron is at least $1.02 Milion dollars as of 30 November 2021. Mr Waldron owns over 14,190 units of BioAtla stock worth over $240,700 and over the last 4 years he sold BCAB stock worth over $779,843.
Sign up
Mr Waldron BCAB stock SEC Form 4 insiders trading
Mr has made over 3 trades of the BioAtla stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 14,190 units of BCAB stock worth $333,181 on 30 November 2021.
The largest trade he's ever made was selling 14,190 units of BioAtla stock on 30 November 2021 worth over $333,181. On average, Mr trades about 1,071 units every 0 days since 2020. As of 30 November 2021 he still owns at least 134,469 units of BioAtla stock.
You can see the complete history of Mr Waldron stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Richard A. Waldron biography
Richard A. Waldron is the Chief Financial Officer at BioAtla.
How old is Mr Waldron?
Mr Waldron is 67, he's been the Chief Financial Officer of BioAtla since . There are no older and 6 younger executives at BioAtla.
What's Mr Waldron's mailing address?
Richard's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Insiders trading at BioAtla
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B... a Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
What does BioAtla do?
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
What does BioAtla's logo look like?
Complete history of Mr Waldron stock trades at BioAtla
BioAtla executives and stock owners
BioAtla executives and other stock owners filed with the SEC include:
-
Dr. Jay M. Short,
Co-Founder, CEO & Chairman -
Scott Andrew Smith,
Pres & Director -
Dr. Eric L. Sievers M.D.,
Chief Medical Officer -
Monica Sullivan,
Sr. VP of Intellectual Property & Contracts -
Christian Vasquez,
VP of Fin., Corp. Controller & Sec. -
Sheri Lydick,
Sr. VP of Commercial Strategy -
Dr. Eric L. Sievers,
Chief Medical Officer -
Dr. Cathy Chang Ph.D.,
Sr. VP of R&D -
Susie Melody,
VP of HR -
Lisa M. Pelton,
Accounting Mang. -
Philippe Martin,
Chief Clinical Devel. & Operations -
Richard A. Waldron,
Chief Financial Officer -
Lawrence Steinman,
-
Asset Management, Lp Chen B...,
-
Inc Pfizer Ventures (Us) Ll...,
-
Christian Vasquez,
See Remarks -
Jay M Phd Short,
Chief Executive Officer -
Richard A Waldron,
Chief Financial Officer -
Carolyn Anderson Short,
See Remarks -
Eric Sievers,
Chief Medical Officer -
Guy Levy,
-
Mary Ann Gray,
-
Susan Moran,
-
Parent Llc Himalaya,
10% owner -
Sylvia Mcbrinn,
-
Eddie Williams,